Royalty Report: Drugs, ribonucleic acid, Drug Discovery – Collection: 344567

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • ribonucleic acid
  • Drug Discovery
  • Respiratory
  • Disease
  • Delivery
  • Antibody
  • Immune
  • Therapeutic
  • Proteins
  • Biotechnology
  • Genome
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344567

License Grant
Licensor grants
For the Development License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Profit-Share Territory, and an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Develop Licensed Products in the Field for the Royalty Territory.

For the Commercialization License, an exclusive right and license, with the right to grant sublicenses, under the Licensor Technology to Commercialize Licensed Products in the Field in the Territory.

For the Manufacturing License, a co-exclusive right and license, with the right to grant sublicenses, under the Licensor Technology, to Manufacture or have Manufactured Licensed Products for Development and Commercialization in the Field for the Territory.

License Property
Patents includes, among other
RNAI Modulation of RSV and Therapeutic Uses Thereof,
Inhaled Treatment for RSV,
Methods and Compositions for Prevention or Treatment of RSV Infection,
Model for RSV Infection,
Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences,
Use of Double Stranded RNA For Identifying Nucleic Acid Sequences That Modulate the Function of a Cell, and, Influenza siRNA Molecules, Expression Constructs. Compositions. and Methods of Use.

Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

ALN-RSV01 is a synthetic double-stranded RNA (dsRNA) oligonucleotide formed by the hybridization of two partially complementary single-strand RN As in which the 3 ends of each strand are capped with two thymidine units (dT).

ALN-RSVO1 drug product is formulated as a sterile phosphate-buffered solution for dilution with normal saline prior to administration.

Licensed Products means any RNAi Product directed to RSV.

RSV means all strains of the respiratory syncytial virus.

RSVOl Product means any product containing Licensors proprietary composition known as ALN-RSVO1.

RSV02 Product means any product containing Licensors proprietary composition designated by the JSC as ALN-RSV02.

Field of Use
ALN-RSV01 is currently in Phase II clinical development for the treatment of respiratory syncytial virus (RSV) infection in adult lung transplant patients, as well as several other potent and specific second-generation RNAi-based RSV inhibitors in pre-clinical studies.

Directly Competitive Product means any therapeutic or prophylactic product that specifically targets RSV. For avoidance of doubt, Directly Competitive Product as to a Party shall not include a product with broad antiviral activity that may also target RSV as long as any Development of such product as a treatment or
prophylaxis of RSV in humans has been limited to discovery, research and preclinical Development work up to, but not including, IND-enabling studies.

Licensee will develop and commercialize such therapeutic RNA interference products for the treatment of respiratory infections in humans caused by RSV, throughout the world, excluding Japan and certain other countries in Asia.

IPSCIO Record ID: 300745

License Grant
Licensor grants the Japanese Licensee a license under and to Licensor Technology to Develop and Commercialize the Licensed Product in the Field in the Licensee Territory. Such license is exclusive for the Royalty Term of the Licensed Product in each country in the Licensee Territory, and shall thereafter be a non-exclusive, fully-paid license to Develop, Manufacture and Commercialize the Licensed Product in the Field in such country.

For the Manufacturing License, Licensor grants a non-exclusive license under Licensor Technology solely for the purpose of Manufacturing the Licensed Product for the Licensee Territory and Licensee grants Licensor a non-exclusive license under Licensee Technology to Manufacture the Licensed Product.

License Property
Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus (RSV) that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression.

The patents include, but are not limited to; RNA interference is mitigated by 21 and 22nt small RNAs;  RNA interference mediating small RNA molecules;  RNA sequence-specific mediators of RNA interference; and, Inhaled treatment for RSV.

Field of Use
Licensee enters this agreement for the treatment of respiratory infections in humans caused by RSV, in Japan and certain other countries in Asia.
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract.

IPSCIO Record ID: 294286

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products for the Target in the Field in the Territory.
License Property
Licensor has intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (RNAi).

Patents include short double-stranded RNAs as therapeutics.

Licensees target is RTP 801, or, DNA•damage-inducible transcript 4.

Field of Use
Field means the use of therapeutic RNAi Products against the Target for the treatment in humans of ocular diseases, loss of hearing, emphysema and pressure sores.

Emphysema is a long-term, progressive disease of the lungs that primarily causes shortness of breath due to over-inflation of the alveoli (air sacs in the lung). In people with emphysema, the lung tissue involved in exchange of gases (oxygen and carbon dioxide) is impaired or destroyed.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 294288

License Grant
Licensor grants a non-exclusive right and license under the Licensor Patent Rights for the sole and exclusive purposes of Researching, Developing and Commercializing Licensed RNAi Products for the Target in the Field in the Territory.
License Property
Licensees target is P53 Tumor protein p53 (Li•Fraumeni syndrome}

Licensor has intellectual property covering technology useful for the discovery, development, manufacture, characterization, or use of therapeutic products that function through RNA interference (RNAi).

Patents include short double-stranded RNAs as therapeutics.

Field of Use
Field means the use of therapeutic RNAi Products against p53 for the treatment of hypoxic injury in humans, including but not limited to renal failure.

Hypoxic injury implies damage to cells resulting only from decreased oxygen tension. This is a relatively unusual pattern of injury in its pure form. Hypoxia can result from decreased atmospheric oxygen concentration, abnormal lung function, and decreased oxygen-carrying capacity in the blood (e.g., severe anemia).

IPSCIO Record ID: 289256

License Grant
Licensor will grant to Canadian Licensee a non-exclusive license to any Licensor Intellectual Property for use in RNAi Products.
License Property
Licensed Product means any product, good, or service covered by a claim of the Licensor controlled Intellectual Property or Licensee controlled Intellectual Property.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 289255

License Grant
For the LNP Technology, Canadian Licensor will grant to Licensee a non-exclusive right to use the Licensor Combined Licensed Technology and the Category 1 Patents for use in developing and commercializing Supplemental Field Products. The license granted to Licensee supersedes and replaces the licenses granted to Licensee by Party A and Licensor in the current Supplemental Agreement. Licensee’s right to sub-license will be on a Sublicensable Product-by-Sublicensable Product basis.
License Property
LNP intellectual property for use in RNAi therapeutic products using LNP technology.

LNP technology relates to where RNAi therapeutics have the potential to treat a broad number of human diseases by “silencing” disease causing genes. RNAi therapeutics, such as “siRNAs,” require delivery technology to be effective systemically. LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Licensor’s LNP platform is being utilized in multiple clinical trials.  LNP technology encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models.

RNAi Product means a product containing, comprised of or based on siRNA, Dicer Substrates, Multivalent RNA, or any derivatives thereof, which are effective in gene function modulation and designed to modulate the function of particular genes or gene products by causing degradation through RNA interference of a Target mRNA to which such siRNAs or siRNA derivatives or moieties are complementary. For greater clarity, an RNAi Product shall not include Antisense.

siRNA means a double-stranded ribonucleic acid (RNA) composition designed to act primarily through an RNA interference mechanism that consists of either (a) two separate oligomers of native or chemically modified RNA that are hybridized to one another along a substantial portion of their lengths, or (b) a single oligomer of native or chemically modified RNA that is hybridized to itself by self-complementary base-pairing along a substantial portion of its length to form a hairpin.

Supplemental Field Product means a product containing, comprised of, or based on Antisense or Gene Therapy.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals.

Field of Use
Field of Use means the delivery of an RNAi Product for any and all purposes.

Supplemental Field means the delivery of (i) single-stranded oligonucleotides, either chemically modified or unmodified, acting through the RNase H mechanism or by or other mechanisms of translational arrest but excluding RNA interference involving RISC (“Antisense”) and (ii) DNA plasmids or messenger RNA (mRNA) either chemically modified or unmodified that are transcribed and/or translated into protein and wherein the pharmacological activity is dependent on expression of the protein (Gene Therapy).

IPSCIO Record ID: 279354

License Grant
Licensor grants to Irish Licensee an exclusive license under the Licensor Patents to make (subject to Licensor’s manufacturing rights set forth below), use, sell, and offer for sale in any country of the world Licensed Products in the Field. Neither Licensee nor Licensor will have the right to develop or commercialize Licensed Products outside the Field without prior written consent of the other Party.

Licensor grants to Licensee (a) an exclusive license to use in any country of the world any method or composition claimed by the Licensor Patents, and (b) a non-exclusive license to use in any country of the world any Licensor Know-How, to research in the Field Lead Compounds, Development Compounds, Backup Compounds, and Licensed Products.

License Property
Licensed Product means a Development Compound for which the Parties obtain the approval from any Regulatory Authority to sell for use by the general public in the Field.

Licensor Patents means a) the patents and applications listed; b) any application that claims priority to the foregoing patents and applications; and c) any patent that issues from any of the applications described in clauses a) and b) above.
US Patent #6,506,559 – Genetic inhibition by double-stranded RNA
US Patent #6,117,657 – Non-nucleotide containing enzymatic nucleic aci
US Patent #6,586,238 – Enzymatic nucleic acids containing 5-and or 3-cap structures

Lead Compound is a Lead selected by JSC for evaluation in the Field.

Development Compound means a Pre-Development Compound that the JSC has designated for clinical development.

Compound means a composition comprising one or more siNAs as active ingredients, known as of the Effective Date or discovered pursuant to this Agreement subsequent to that date, against the Licensee Named Targets in the Field.

Backup Compound means a Lead Compound that the JSC has selected as a backup candidate for clinical development.

JSC means the Joint Steering Committee.

Field of Use
Field means conditions and diseases affecting the eve and treatments for such conditions and diseases. Such conditions and diseases include, for example, diabetic retinopathy and ocular adenoviral infection, but this does not mean that the Field encompasses the treatment outside the eye of diabetes or adenoviral infection, respectively.

Licensee is to develop Sirna-027, a RNAi-based therapeutic currently in Phase 1 for age-related macular degeneration (AMD), and to discover and develop other RNAi-based therapeutics against select gene targets in ophthalmic diseases.

IPSCIO Record ID: 282391

License Grant
Licensor grants the Licensee of the Netherlands an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensor IP, to
—  Develop, manufacture, make, have made, distribute, market, promote, sell, have sold, offer for sale, import and otherwise Commercialize Worldwide License Products in the Worldwide Territory.
—  Develop, distribute, market, promote, sell, have sold, offer for sale, import and otherwise Commercialize Limited License Products in the Limited Territory.
License Property
Licensor has developed the Limited License Products and MabIgX Platform, and includes patents.

MabIgX Technology means the Licensor technology for the identification of antibody producing B-cells,  MabIgX® Antibody Discovery Platform & Development of Rare, Potent Human mAbs.  The MabIgX technology is designed to rapidly identify rare, potent antibody-producing B-cells from patients who successfully overcame an infection, then quickly convert the discovered B-cell into a stable manufacturing substrate. This technology immortalizes and stabilizes the antibody-producing human B-cells from the patient, enabling large scale manufacturing of fully human mAbs for treatment of the masses.

AR-301, Fully Human mAb Against Staphylococcus aureus,  (or Salvecin®) is a fully human monoclonal IgG1 antibody (mAb) that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA).   AR-301 protects against alpha-toxin mediated destruction of host cells, preserving the human immune cells.

AR-105 is Broadly Active Human Monoclonal Antibody (mAb) Against Pseudomonas aeruginosa.  The Gram negative bacterium Pseudomonas aeruginosa is one of the most important public health pathogens and is associated with a number of difficult-to-treat infections such as pneumonia, bacteremia, and cystic fibrosis lung infection.  

AR-101, Fully Human mAb Against Pseudomonas aeruginosa LPS serotype O11, (or AerumabTM) is a highly specific monoclonal antibody targeted against P. aeruginosa lipopolysaccharide serotype O11. Binding of AR-101 to P. aeruginosa bacteria facilitates human complement binding and improves immune recognition and destruction by circulating human phagocytes. AR-101’s mechanism of action is distinct from mechanisms of antibiotic resistance, and is effective against multidrug resistant LPS serotype O11 P. aeruginosa clinical isolates.  

AR-201, Fully Human mAb Against Respiratory Syncytial Virus, is a human IgG1 monoclonal antibody (mAb) directed against the F-protein of respiratory syncytial virus (RSV).   AR-201 was isolated from antibody-producing B-cells of an infant infected with RSV.  This mAb broadly neutralizes RSV clinical isolates, including RSV strains that are resistant to standard of care mAb Synagis®.  Licensed Product shall mean the Worldwide License Products, and the Limited License Products.

Limited License Products shall mean certain of Licensor’s products currently in development, comprising the products known as AR-301, AR-105, AR-101.

Field of Use
The field of use in each case Indication is to be a target to an infectious disease predominantly of economic impact in the Developing World.

Licensee is granted right to Licensor' clinical stage programs AR-301 (ventilator associated pneumonia), AR-105 (ventilator associated pneumonia), and AR-101 (hospital acquired pneumonia

AR-301’s mode of action is independent of the antibiotic resistance profile of S. aureus and it is active against infections caused by both MRSA and MSSA.

AR-105 (Aerucin®) is a broadly active, fully human IgG1 monoclonal antibody targeted against P. aeruginosa alginate, a widely distributed cell surface polysaccharide involved in surface adhesion, biofilm formation, and protection against the human immune system.

AR-101 is intended to be a first-line adjunctive therapy for patients with severe P. aeruginosa pneumonia being treated in intensive care units, and has orphan drug designation from the U.S. FDA and Europe’s EMA regulatory agencies.

AR-201 is engineered to have long plasma half-life sufficient to last through the duration of the RSV infection season in a single dose.

IPSCIO Record ID: 289173

License Grant
Party A, a Canadian University, hereby assigns to Licensee all of Party A’s right, title and interest in and to U.S. Patent Application No. 11/807,872, with no additional payment due to Party B and will record such assignment with the U.S. Patent and Trademark Office.

The Parties shall direct their respective counsel to execute Stipulations of Dismissal with Prejudice dismissing all claims and counterclaims that were or could have been asserted in the Massachusetts State Court Action, U.S. Infringement Action, Canadian Infringement Action, and B.C. Action, and in the case of the Interference Proceeding, a Request for Adverse Judgment providing that Licensee concedes priority to Party A with respect to all claims that correspond to Counts 1-5, i.e., claims 34, 36, 38, and 40-43 of Party A U.S. Application 11/807,872; claims 1-6, 8, 10, 12-18, 21-22, and 32-33 of Licensee U.S. Patent 7,718,629; and claims 32-38 of Licensee U.S. Application 13/165,568, and requesting that an adverse judgment be entered against Licensee as to these claims and priority be awarded to Party A for U.S. Application 11/807,872.

License Property
U.S. Patent 7,718,629 – Compositions and methods for inhibiting expression of Eg5 gene
Patent certains to intellectual property (IP) elements related to lipid nanoparticle (LNP) technology for RNAi therapeutics.

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development.

Field of Use
By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 237256

License Grant
With this agreement, the English Licensor and the Licensee wish to settle legal proceedings by way of variation to the Patent License Agreement.   The original agreement is non-exclusive.
License Property
The amendment clarifies the licensed property includes, for the avoidance of doubt, Synagis.  The patent 6,632,927, is for the present invention relates to humanised antibody molecules.

Synagis is a humanized monoclonal antibody (“MAb”) approved for marketing in 1998 by the U.S. Food and Drug Administration (the “FDA”) for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (“RSV”) in pediatric patients at high risk of acquiring RSV disease (pneumonia and bronchiolitis).

Field of Use
Synagis® is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.

IPSCIO Record ID: 369239

License Grant
For the Grant of License, Licensor grants to the German Licensee
— an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Proprietary Information to have access to testing services performed by Licensor using the RSV Assay for the purpose of identifying Plasma donors with elevated amounts of RSV antibodies, which Plasma Licensee may use in the production of the Product and Finished Product and related purposes for sale in the Territory;
—  an exclusive license in the Territory to reference the Licensor Proprietary Information, but not obtain access to such Proprietary Information, for the purpose of seeking Regulatory Approval of the Product and Finished Product in the Territory; and,
— an exclusive license, with the right to grant sublicenses in the Territory, under the Licensor Proprietary Information to manufacture and have manufactured Product and Finished Product to be distributed in the Territory and to Commercialize the Product and Finished Product in the Territory.
License Property
Licensor is engaged in the business of developing and commercializing human plasma and plasma-derived therapeutics, including an Human Immunoglobulin with standardized elevated levels of Respiratory Syncytial Virus antibodies.

Licensor has established, qualified and validated a proprietary microneutralization assay process and procedures, through which Licensor is able to identify plasma donors with naturally occurring elevated amounts of anti-RSV antibodies, the RSV Assay.

Product means RSV, Respiratory syncytial virus, antibody enriched Human Immune Globulin bulk drug substance manufactured from human plasma containing elevated anti-RSV antibody levels that were tested using the RSV Assay.

Licensor's lead product candidate, RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies to respiratory syncytial virus (RSV). Licensor is pursuing an indication for the use of this specialty intravenous immune globulin (IGIV) product for treatment of patients diagnosed with PIDD.

Primary Immune Deficiency Disease (PIDD) is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly. PIDD patients are more vulnerable to infections and more likely to suffer complications from these infections.

RI-002 has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint.

Field of Use
Licensee manufactures preparations derived from human blood plasma using state-of-the-art biotechnological processes, which preparations are used as immunotherapeutic agents in the treatment of various deficiencies, diseases, infections, and other disorders.

IPSCIO Record ID: 294285

License Grant
For the Exclusive Licenses, Licensor grants an exclusive license including the right to sublicense, under the Licensor Patent Rights and Licensor Technology to develop, make, have made, use, sell, offer for sale and import Biomolecules and Licensed Products in the Territory.

For the Non-Exclusive Research Licenses, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, to use solely for research done by Licensee or its Affiliates or by Third Party contractors for Licensee or its Affiliates the Licensor Technology, excluding any Licensor Technology that is now or hereafter during the Term covered by claims in issued patents or published patent applications disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology,know-how and scientific and technical information relating to Biomolecules and Licensed Products.

Applicable Biomolecule means a Biomolecule as to which Licensor at any time during the Term commenced IND-enabling toxicity studies or clinical trials.

Product means any product, including any pharmaceutical product or diagnostic product, which contains any Biomolecule, either alone or in combination with any other active pharmaceutical ingredient, in all formulations and strengths for all uses.

Combination Product means any pharmaceutical product containing a Biomolecule and one or more other active phannaceutical ingredients.

Field of Use
License relates to Licensor’s human gene RTP-801 and to molecules that modify its expression or function under a new agreement between the two companies. RTP-801 is involved in the development of pathologic blood vessels that accelerate the progression of age-related macular degeneration (AMD).   Based on preclinical models, it is believed that AMD can be treated by blocking the expression of the RTP-801 gene through RNA interference or RNAi.

Licensee has extensive experience and expertise in the development and commercialization of pharmaceutical products.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 279378

License Grant
The Parties have an agreement to develop technology useful for in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.

For the profit sharing products
For the Development Licenses, to Develop Profit-Sharing Products in such Program in the Field in the Territory; and Licensor grants a  worldwide, Co-exclusive license, sublicenseable  to its Affiliates, under and to any and all Licensor RNAi Technology, Licensor RNAi Patent Rights, Licensor Collaboration Inventions, Licensor Therapeutic Collaboration IP, Licensors interest in Joint Collaboration IP and Licensor RNAi Novel Target IP which are Controlled by Licensor or the Third Party Licensor or their wholly-owned subsidiaries to Develop Profit-Sharing Products in such Program in the Field in the Territory.

For the Commercialization Licenses, upon Licensees exercise of its U.S. Co-Promotion Option, Licensor grants Licensee a Co-exclusive license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the United States.

For the Manufacturing Licenses, Licensor grants Licensee a non-exclusive license under and to any and all Licensor Technology to Manufacture Profit-Sharing Products in the Field for the Territory.

For the Product Trademark Licenses, Licensor shall grant a Co-exclusive license to use such Product Trademarks to perform its Development obligations under this Agreement with respect to such Profit-Sharing Product.  

Licensor grants a Co-exclusive license to use the Product Trademarks selected by Licensor and approved by the JSC for such Profit-Sharing Product to Commercialize such Profit-Sharing Product in the Field in the United States.

Licensor grants a non-exclusive license in the Territory, under Licensor Broad RNAi Patent Rights that were Controlled by Licensor or the Third Party Licensor or their wholly-owned subsidiaries during the Technology Collaboration Term, Licensor Broad RNAi Technology that was Controlled by Licensor or the Third Party  or their wholly-owned subsidiaries during the Technology Collaboration Term, Licensors interest in Joint Collaboration Patent Rights, and Licensor-Assigned Therapeutic Collaboration Inventions.

License Property
The developed technology will relate to in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.

Field of Use
The Field shall mean the treatment and/or prophylaxis of diseases in humans with RNAi Therapeutic Products.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

IPSCIO Record ID: 239031

License Grant
The original agreement is to co-promote the Product in the Territory.  This amendment to the Agreement is to extend the special consideration for Synagis sales.
License Property
Synagis is an antibody that provides the immune system with an increased ability to prevent infection.
Field of Use
The use is for respiratory syncytial virus ('RSV'), the leading cause of lower respiratory tract infections and pneumonia in infants and children worldwide.

IPSCIO Record ID: 248304

License Grant
Licensor, a not-for-profit clinical research center, hospital and graduate medical school, hereby grants to Licensee (I) an exclusive royalty-bearing right and license under the Patent Rights to manufacture, use. offer for sale, sell and import Licensed Products in Field 1, in the Territory, and (ii) an exclusive royalty-bearing right and license under the Patent Rights, subject to such terms and conditions of the Nastech Non-Exclusive License as are applicable and in full force and effect, to manufacture, use, offer for sale, sell and import Licensed Products in Field 2, in the Territory; except that Licensees rights in the Fields with respect to diagnostic uses of Licensed  Products are as set forth in this agreement.

Licensor hereby grants to Licensee an exclusive royalty-bearing right and license under the Patent Rights to manufacture, use, offer for sale, sell and import Licensed Products for human diagnostic uses in the Territory in the Fields solely as expressly set forth in this Agreement. From time to time during the term of this Agreement, Licensee shall have the right, on notice to Licensor, to nominate a specific Licensed Product for diagnostic uses, which Licensed Product shall. at the time of such nomination, be currently the subject of a discovery or development program of Licensee or a Sublicensee or approved for a therapeutic use in one of the Fields.

License Property
Licensed Product means a pharmaceutical product (including, without limitation, kits, component sets or components thereof, regardless of concentration or formulation) that [A] (i) is Covered by a Valid Claim, (ii) manufactured by a process or used in a method Covered by a Valid Claim, or (iii) contains, as an active ingredient, any substance the manufacture, use, offer for sale or sale of which is Covered by a Valid Claim and [BJ targets
(1) one or more genomes or RNA transcripts of a virus or a pathogenic organism (Pathogen RNA), or (2) RNAs that Localize in. or traffic to, the cytoplasm (Cytoplasmic RNA). For the avoidance of doubt, a product otherwise meeting the criteria set forth that targets a Pathogen RNA and also targets Cytoplasmic RNAs shall be considered a Licensed Product. For the purposes of the definition of Licensed Product, targets means possessing a degree of Watson-Crick base pairing between the Licensed Product and either Pathogen RNA or Cytoplasmic RNA that is sufficient to promote RNA induced silencing. By way of further clarification, Licensed Product shall include a product manufactured in a country in which such manufacture is Covered by a Valid Claim and thereafter exported to and sold in a country in which no Valid Claim exists.

Patent Rights means
11/079,906 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.
11/079,476 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.
11/797,296 – Methods and compositions for the specific inhibition of gene expression by double stranded RNA.

Field of Use
Fields means Field 1 and Field 2.  Field 1 means the diagnosis. prevention and treatment of disease in humans (a) by the delivery of a Licensed Product directly into the eye or onto the surface of the eye, or (b) by the delivery of a Licensed Product directly into the aural canal. (c) by targeting anv virus except (i) the influenza A, inJluenza B or influenza C virus, (ii) the respiratory syncytial virus, or (iii) the meta pneumovirus.  Field 2 means the diagnosis. prevention and treatment of disease in humans OTHER THAN (a) by the delivery of a Licensed Product directly into the eye or onto the surface of the eye, or (b) by the delivery of a Licensed Product directly into the aural canal, or (c) by use of a Licensed Product to target any specific virus.

IPSCIO Record ID: 245938

License Grant
The Parties agree in collaborating, on the terms and conditions set forth in this agreement, in the discovery and development of RNAi Therapeutics (as defined below) directed to the JC virus for use in the Field.
License Property
RNAi Therapeutic means a therapeutic product containing, comprised of or based on one or more siRNAs or siRNA derivatives or other moieties effective in gene function modulation and designed to modulate the function of particular genes or gene products through RNA interference.

JCV means the human polyomavirus known as JC virus.

PML means progressive multifocal leukoencephalopathy.

Discovery or Discover means any and all activities to discover and characterize potential Development Candidates during the Discovery Term prior to the initiation of IND-Enabling Toxicology Studies, including without limitation, the research and development activities related to the generation, characterization, optimization, construction, synthesis, use and production of potential Development Candidates.

Development or Develop means any preclinical and clinical activity to develop a Selected RNAi Therapeutic, beginning with IND-Enabling GLP Toxicology Studies and ending upon Regulatory Approval and completion of any post-approval regulatory commitments.

Field of Use
Field means the prophylaxis and/or treatment of progressive multifocal leukoencephalopathy (PML).

Progressive multifocal leukoencephalopathy (PML) is a disease of the white matter of the brain, caused by a virus infection that targets cells that make myelin–the material that insulates nerve cells (neurons).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.